

SHORT COMMUNICATION

Visfatin Is Actively Secreted In Vitro From U-937 Macrophages, but Only Passively Released From 3T3-L1 Adipocytes and HepG2 Hepatocytes

P. SVOBODA^{1,2}, E. KRÍŽOVÁ¹, K. ČEŇKOVÁ¹, K. VÁPENKOVÁ¹, J. ZÍDKOVÁ¹, V. ZÍDEK², V. ŠKOP¹

¹Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague, Czech Republic, ²Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic

Received May 2, 2016

Accepted January 25, 2017

On-line April 12, 2017

Summary

Visfatin is a multi-functional molecule that can act intracellularly and extracellularly as an adipokine, cytokine and enzyme. One of the main questions concerning visfatin is the mechanism of its secretion; whether, how and from which cells visfatin is released. The objective of this *in vitro* study was to observe the active secretion of visfatin from 3T3-L1 preadipocytes and adipocytes, HepG2 hepatocytes, U-937, THP-1 and HL-60 monocytes and macrophages. The amount of visfatin in media and cell lysate was always related to the intracellular enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), to exclude the passive release of visfatin. Visfatin was not found in media of 3T3-L1 preadipocytes. In media of 3T3-L1 adipocytes and HepG2 hepatocytes, the ratio of visfatin to the amount of GAPDH was identical to cell lysates. Hence, it is likely that these cells do not actively secrete visfatin in a significant manner. However, we found that significant producers of visfatin are differentiated macrophages and that the amount of secreted visfatin depends on used cell line and it is affected by the mode of differentiation. Results show that 3T3-L1 adipocytes and HepG2 hepatocytes released visfatin only passively during the cell death. U-937 macrophages secrete visfatin in the greatest level from all of the tested cell lines.

Key words

Nampt • Visfatin • Active secretion • Adipocytes • Hepatocytes • Macrophages

Corresponding author

V. Škop, Department of Biochemistry and Microbiology, University of Chemistry and Technology, Technická 5, 166 28 Prague 6 – Dejvice, Czech Republic. E-mail: skopv@vscht.cz

Visfatin was discovered as an insulin-mimetic adipokine produced predominantly by visceral adipose tissue (Fukuhara *et al.* 2005). This multi-functional molecule exhibits intracellular and also extracellular action. Besides its function as an insulin-mimetic adipokine, visfatin is also effective as an inflammatory cytokine pre-B cell colony-enhancing factor (PBEF) and as an important enzyme catalyzing the rate limiting step in the nicotinamide adenine dinucleotide (NAD) biosynthetic pathway – nicotinamide phosphoribosyl-transferase (Nampt) (Rongvaux *et al.* 2002, Sommer *et al.* 2008). This enzymatic reaction, as well as visfatin function, is located both intracellularly (Kitani *et al.* 2003, Tanaka *et al.* 2007) and extracellularly (Jacques *et al.* 2012, Zhao *et al.* 2014). There is still a lot of controversy about this protein. The first issue is the function of visfatin as a secreted cytokine and adipokine. Some authors associate its extracellular function with the production of NAD (Revollo *et al.* 2007), because the membrane receptor of visfatin on target cells has thus far not been conclusively determined. Conversely, other authors describe the action of visfatin independently on its enzyme activity and *via* association with signaling

kinase cascade (Garten *et al.* 2015, Lin *et al.* 2016, Soncini *et al.* 2014). Another issue of visfatin represents its mechanism of secretion. Even though its extracellular function has been described, the process of how visfatin is released from cells is still unclear.

Visfatin is not secreted by a classical secretory pathway using endoplasmic reticulum and Golgi complex and it has been hypothesized that visfatin is actively secreted by an unknown non-classical pathway (Tanaka *et al.* 2007). According to the visfatin function, adipocytes and immune cells are described as the most important producers of this protein to the extracellular space (Curat *et al.* 2006, Garcia-Serrano *et al.* 2015, Tanaka *et al.* 2007). However, some ability to release visfatin has been detected in many cell types, including hepatocytes (Garten *et al.* 2010), glia cells (Zhao *et al.* 2014), pancreatic β -cells (Kover *et al.* 2013), melanoma cells (Grolla *et al.* 2015) and endothelial cells (Romacho *et al.* 2013). Nevertheless, the secretory mechanism and cellular receptor of visfatin have not been determined yet and thus the question about its active secretion remains unresolved. The presence of visfatin in the extracellular space might be due to its non-specific release during cell death and lysis, at least in certain case of cell types (Kitani *et al.* 2003, Stephens and Vidal-Puig 2006, Zhao *et al.* 2014).

In this short communication report, we examined the active secretion of visfatin from different cell types *in vitro* – mouse 3T3-L1 preadipocytes and adipocytes; human HepG2 hepatocytes; and human U-937, HL-60 and THP-1 monocytes and macrophages. To exclude passive release during cell death and lysis, internal control of active secretion must be performed. Simultaneously with the target protein, it is necessary to quantify the non-secreted intracellular protein control in culture media and cell lysates. The value that reflects active secretion is the increased ratio of quantities of the target protein and non-secreted protein control in media compared to cell lysates. Selection of the protein control is a critical step: it should be located in the same compartment as studied protein and must not be able to form multimeric structures or associate with membranes, because these factors affect its release during cell death and lysis. For instance, β -actin which is frequently used, is not one of the most eligible candidate because of polymerisation. In this study, we used glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the intracellular protein control. GAPDH is a soluble cytosolic enzyme; therefore, its passive release during cell death should be

the same as visfatin.

3T3-L1 preadipocytes were maintained in DMEM (HyClone) containing 10 % FBS (Biochrom) and 4 mmol.l⁻¹ L-glutamine (HyClone). They were subsequently differentiated into adipocytes, as was described previously (Skop *et al.* 2014), using dexamethasone, isobutylmethylxanthine and insulin. HepG2 hepatocytes were maintained in MEM (HyClone) supplemented with 10 % FBS, 2 mmol.l⁻¹ L-glutamine and non-essential amino acids (Sigma). U-937, HL-60 and THP-1 monocytes were maintained in RPMI-1640 medium (HyClone) containing 10 % FBS and 2 mmol.l⁻¹ L-glutamine. They were subsequently differentiated into macrophages by incubation with 100 μ g.l⁻¹ of phorbol 12-myristate 13-acetate (PMA, Sigma) for 24 h (U-937: 100 μ g.l⁻¹, HL-60 and THP-1: 200 μ g.l⁻¹). During this time, most of cells adhered to the dish surface. Next, the medium was exchanged for a medium without PMA, while all PMA-treated non-adherent cells were centrifuged and returned to the original dish to finish differentiation. Cells were fully differentiated after 48 h in the absence of PMA. To analyze the content of visfatin and GAPDH in lysates and media, cells were washed and cultivated in a serum-free medium (SFM) for 18 h. Thereafter, the medium was collected and centrifuged (200 rcf, 5 min). Proteins from supernatants were precipitated using trichloroacetic acid (TCA) in a final concentration of 0.575 mol.l⁻¹ (1 h on ice). Precipitated proteins were sedimented by centrifugation (18 000 rcf, 20 min, 2 °C). The pellet was resuspended in a loading buffer (50 % glycerol, 0.25 mol.l⁻¹ Tris-HCl, pH 6.8, 25 % 2-mercaptoethanol, 0.35 mol.l⁻¹ SDS, 0.5 % bromophenol blue) and the rest of the TCA was neutralized by NaOH. This sample was run in SDS-PAGE. After cultivation in SFM, the cells were lysed using a lysis buffer (0.01 mol.l⁻¹ NaH₂PO₄, 0.01 mol.l⁻¹ Na₂HPO₄, 0.15 mol.l⁻¹ NaCl, 1 % sodium deoxycholate, 1 % Triton X-100) and sonication. Forty μ g of the total proteins (measured using BCA assay, Pierce) were run in SDS-PAGE. After electrophoresis, proteins were electrotransferred to nitrocellulose membranes, which were then blocked by 3 % bovine serum albumin (Sigma). Blots were incubated with a mixture of primary rabbit antibodies directed against visfatin (1:5 000, RB-08-0003, RayBiotech) and GAPDH (1:20 000, G9545, Sigma). Antibody binding was then revealed with peroxidase-labelled mouse secondary antibody directed against rabbit IgG (1:5 000, W401B, Promega). Membranes were visualized using chemiluminescent

reagents (West Pico, Pierce). Quantification of the bands was performed using Image J software (NIH, USA). One-way ANOVA followed by Tukey's test ($p < 0.05$) was performed to compare media against lysate.

The results dealing with secretion of visfatin from 3T3-L1, HepG2 and U-937 cells are shown in Figure 1. When studying secretion of visfatin from 3T3-L1 cells, we found neither visfatin nor GAPDH in culture media of preadipocytes. Differentiated 3T3-L1 adipocytes always released visfatin with GAPDH and the ratio of the content of these two proteins in media was approximately equal to the ratio of intracellular content. In HepG2 hepatocytes, we obtained a similar result to

3T3-L1 adipocytes, which suggests that visfatin is released from these two cell lines during spontaneous cell lysis. A different situation occurred in the case of U-937 cells. U-937 monocytes exhibited a mildly increased visfatin-to-GAPDH ratio in media compared to lysates, indicating a low level of active visfatin secretion. Interestingly, differentiated U-937 macrophages released a high amount of visfatin in media, while GAPDH was only weakly detected there. In addition, the ratio of the content of visfatin-to-GAPDH was substantially higher in media compared to cell lysates, demonstrating the active secretion of visfatin from this cell line.




Fig. 1. Representative Western blots and quantification of intracellular and extracellular visfatin and GAPDH from 3T3-L1 preadipocytes, 3T3-L1 adipocytes, HepG2 hepatocytes, U-937 monocytes and U-937 macrophages. Values are mean \pm SE, $n=3$. ANOVA analysis: * $P < 0.05$, *** $P < 0.01$ media vs. lysates.

Two other human monocyte lines with macrophage differentiation ability (THP-1 and HL-60) were tested on active secretion of visfatin to confirm the tissue specificity of macrophages as cells actively secreting visfatin. Furthermore, various differentiation protocols of U-937 cells were used to study whether mode of differentiation affects visfatin secretion. THP-1 and HL-60 macrophages exhibited significantly increased visfatin-to-GAPDH ratio in media compared to lysates, which shows that both of these cell lines actively secreted visfatin (Fig. 2A). Results further show that from tested macrophage cell lines, U-937 cells secreted the greatest level of visfatin. Moreover, the quantity of visfatin secreted into media depends on the differentiation protocol in U-937 cell line (Fig. 2B), where the amount of secreted visfatin increases with increasing concentration of the differentiation inducer, PMA.

The question concerning the mechanism of visfatin secretion remains unanswered. Our results show that 3T3-L1 preadipocytes, adipocytes and HepG2

hepatocytes do not secrete visfatin actively. However, this is not in agreement with some previously reported studies (Garten *et al.* 2010, Tanaka *et al.* 2007). Secretion of visfatin from 3T3-L1 adipocytes was reported for the first time by Fukuhara *et al.* (2005) in the original article describing visfatin as an adipokine. However, an internal control of active secretion was absent from this study. Moreover, the retraction of the article two years after publication caused further doubt on the validity of their results (Fukuhara *et al.* 2007). The same scientific group published an article dealing directly with secretion of visfatin from 3T3-L1 cells (Tanaka *et al.* 2007); however, no comparison with a non-secreted protein control or any assay of cell death or lysis was performed. In other reports that studied the influence of effectors on the secretion of visfatin from 3T3-L1 cells, there has been an absence of any internal control of active secretion and visfatin concentration in media was very low (Eseberri *et al.* 2013, Li *et al.* 2014).




Fig. 2. Representative Western blots and quantification of intracellular and extracellular visfatin and GAPDH from HL-60 and THP-1 monocytes and macrophages (**A**), U-937 macrophages differentiated using various concentrations of PMA (**B**). Values are mean \pm SE, $n=3$. ANOVA analysis: * $P<0.05$, *** $P<0.01$ media vs. lysates, # $P<0.05$ vs. $10 \mu\text{g.l}^{-1}$ PMA, † $P<0.05$ vs. $100 \mu\text{g.l}^{-1}$.

Thus far, only one work has examined the secretion of visfatin from HepG2 hepatocytes (Garten *et al.* 2010). In this study, the active secretion of visfatin was found from HepG2 cells and primary hepatocytes. To exclude passive release, the level of cell death was determined by adenylate kinase assay. Although there was no increase in cell death parameters over a 3-day cultivation in serum-free media, the concentration of visfatin in media increased continually during that time (Garten *et al.* 2010). On the contrary, in our experiments, we were not able to cultivate HepG2 cells in serum-free media without a certain level of cell death. This was accompanied by the release of GAPDH and visfatin into the extracellular space. Due to this problem, we cannot exclude the active secretion of visfatin in some small extent by HepG2 cells, because, theoretically, the low concentration of actively secreted visfatin would be obscured by the higher level of visfatin released during cell death. According to our results, HepG2 hepatocytes and 3T3-L1 adipocytes do not seem to produce visfatin in significant quantities and, therefore, these cell lines do not provide a good model for studying visfatin secretion.

Because secretion of visfatin from macrophages has been previously shown (Curat *et al.* 2006, Schilling and Hauschildt 2012, Wang *et al.* 2016), the other cell types we examined were U-937, THP-1 and HL-60 monocytes and macrophages. All of tested human macrophages differentiated by PMA substantially secreted visfatin. We thus hypothesize that macrophages

are the main producers of visfatin. This hypothesis is in agreement with results showing increased serum levels of visfatin in obesity and metabolic syndrome (Chang *et al.* 2011), as macrophages naturally occurs in white adipose tissue (WAT) and their number and production of cytokines is increased in obesity (Ghazarian *et al.* 2015). Since the amount of secreted visfatin differs between tested macrophage cell lines, we further tested whether mode of differentiation affects visfatin secretion. We found that the amount of visfatin secreted from U-937 macrophages was significantly affected by concentration of the differentiation agent PMA, even though all of these cells had a macrophage phenotype (adherent growth, stopped cell division) and intracellular visfatin content only slightly differed. Various surrounding conditions during macrophage differentiation and activation in body result in the formation of diverse macrophage sub-populations, which secrete diverse spectra of cytokines (McNelis and Olefsky 2014, Murray and Wynn 2011). We may thus suppose that visfatin is secreted from diverse macrophage sub-populations in a different manner.

We may conclude that, in our *in vitro* experiments, U-937, THP-1 and HL-60 macrophages significantly and actively secreted visfatin, but in case of 3T3-L1 adipocytes or HepG2 hepatocytes active secretion of visfatin was not observed. The highest secretion of visfatin was found in U-937 macrophages, therefore, this cell line is the most suitable for visfatin

secretion mechanism study from all of the tested cells. Since visfatin serum content has been hypothesized to play an important role in type 2 diabetes or cardiovascular disease (Sun *et al.* 2013), our results provide a new insight into the complex role of macrophages in the pathogenesis of such diseases.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

This study was supported by grant 16-04859S and grant 13-04580S from Czech Science Foundation. We wish to thank Michael FitzGerald for his help in editing the text.

References

- CHANG YH, CHANG DM, LIN KC, SHIN SJ, LEE YJ: Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. *Diabetes Metab Res Rev* **27**: 515-527, 2011.
- CURAT CA, WEGNER V, SENGENÈS C, MIRANVILLE A, TONUS C, BUSSE R, BOULOUMIÉ A: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. *Diabetologia* **49**: 744-747, 2006.
- ESEBERRI I, LASA A, CHURRUCA I, PORTILLO MP: Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. *PLoS One* **8**: e63918, 2013.
- FUKUHARA A, MATSUDA M, NISHIZAWA M, SEGAWA K, TANAKA M, KISHIMOTO K, MATSUKI Y, MURAKAMI M, ICHISAKA T, MURAKAMI H, WATANABE E, TAKAGI T, AKIYOSHI M, OHTSUBO T, KIHARA S, YAMASHITA S, MAKISHIMA M, FUNAHASHI T, YAMANAKA S, HIRAMATSU R, MATSUZAWA Y, SHIMOMURA I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science* **307**: 426-430, 2005.
- FUKUHARA A, MATSUDA M, NISHIZAWA M, SEGAWA K, TANAKA M, KISHIMOTO K, MATSUKI Y, MURAKAMI M, ICHISAKA T, MURAKAMI H, WATANABE E, TAKAGI T, AKIYOSHI M, OHTSUBO T, KIHARA S, YAMASHITA S, MAKISHIMA M, FUNAHASHI T, YAMANAKA S, HIRAMATSU R, MATSUZAWA Y, SHIMOMURA I: Retraction. *Science* **318**: 565, 2007.
- GARCIA-SERRANO S, GUTIÉRREZ-REPISO C, GONZALO M, GARCIA-ARNES J, VALDES S, SORIGUER F, PEREZ-VALERO V, ALAMINOS-CASTILLO MA, FRANCISCO COBOS-BRAVO J, MORENO-RUIZ FJ, RODRIGUEZ-CAÑETE A, RODRÍGUEZ-PACHECO F, GARCIA-ESCOBAR E, GARCÍA-FUENTES E: C-peptide modifies leptin and visfatin secretion in human adipose tissue. *Obesity (Silver Spring)* **23**: 1607-1615, 2015.
- GARTEN A, PETZOLD S, BARNIKOL-OETTLER A, KÖRNER A, THASLER WE, KRATZSCH J, KIESS W, GEBHARDT R: Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. *Biochem Biophys Res Commun* **391**: 376-381, 2010.
- GARTEN A, SCHUSTER S, PENKE M, GORSKI T, DE GIORGIS T, KIESS W: Physiological and pathophysiological roles of NAMPT and NAD metabolism. *Nat Rev Endocrinol* **11**: 535-546, 2015.
- GHAZARIAN M, LUCK H, REVELO XS, WINER S, WINER DA: Immunopathology of adipose tissue during metabolic syndrome. *Turk Patoloji Derg* **31** (Suppl 1): 172-180, 2015.
- GROLLA AA, TORRETTA S, GNEMMI I, AMORUSO A, ORSOMANDO G, GATTI M, CALDARELLI A, LIM D, PENENGO L, BRUNELLESCHI S, GENAZZANI AA, TRAVELLI C: Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma. *Pigment Cell Melanoma Res* **28**: 718-729, 2015.

Abbreviations

DMEM – Dulbecco's modified Eagle's medium, FBS – fetal bovine serum, GAPDH – glyceraldehyde 3-phosphate dehydrogenase, MEM – minimum essential medium, NAD – nicotinamide adenine dinucleotide, Nampt – nicotinamide phosphoribosyltransferase, PAGE – polyacrylamide gel electrophoresis, PBEF – pre-B cell colony-enhancing factor, PMA – phorbol 12-myristate 13-acetate, RPMI-1640 – Roswell Park Memorial Institute 1640, SDS – sodium dodecyl sulfate, SFM – serum-free medium, TCA – trichloroacetic acid, WAT – white adipose tissue.

- JACQUES C, HOLZENBERGER M, MLADENOVIC Z, SALVAT C, PECCHI E, BERENBAUM F, GOSSET M: Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. *J Biol Chem* **287**: 15100-15108, 2012.
- KITANI T, OKUNO S, FUJISAWA H: Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. *FEBS Lett* **544**: 74-78, 2003.
- KOVER K, TONG PY, WATKINS D, CLEMENTS M, STEHNO-BITTEL L, NOVIKOVA L, BITTEL D, KIBIRYEVA N, STUHLSATZ J, YAN Y, YE SQ, MOORE WV: Expression and regulation of nampt in human islets. *PLoS One* **8**: e58767, 2013.
- LI X, JIANG L, YANG M, WU YW, SUN SX, SUN JZ: CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes. *Endocr J* **61**: 1153-1162, 2014.
- LIN YT, JIAN DY, KWOK CF, HO LT, JUAN CC: Visfatin promotes foam cell formation by dysregulating CD36, SRA, ABCA1, and ABCG1 expression in RAW264.7 macrophages. *Shock* **45**: 460-468, 2016.
- MCNELIS JC, OLEFSKY JM: Macrophages, immunity, and metabolic disease. *Immunity* **41**: 36-48, 2014.
- MURRAY PJ, WYNN TA: Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol* **11**: 723-737, 2011.
- REVOLLO JR, KÖRNER A, MILLS KF, SATOH A, WANG T, GARTEN A, DASGUPTA B, SASAKI Y, WOLBERGER C, TOWNSEND RR, MILBRANDT J, KIESS W, IMAI S: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. *Cell Metab* **6**: 363-375, 2007.
- ROMACHO T, VILLALOBOS LA, CERCAS E, CARRARO R, SÁNCHEZ-FERRER CF, PEIRÓ C: Visfatin as a novel mediator released by inflamed human endothelial cells. *PLoS One* **8**: e78283, 2013.
- RONGVAUX A, SHEA RJ, MULKS MH, GIGOT D, URBAIN J, LEO O, ANDRIS F: Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. *Eur J Immunol* **32**: 3225-3234, 2002.
- SCHILLING E, HAUSCHILDT S: Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-activated human monocytes. *Innate Immun* **18**: 738-744, 2012.
- SKOP V, CAHOVA M, DANKOVA H, PAPACKOVA Z, PALENICKOVA E, SVOBODA P, ZIDKOVA J, KAZDOVA L: Autophagy inhibition in early but not in later stages prevents 3T3-L1 differentiation: effect on mitochondrial remodeling. *Differentiation* **87**: 220-229, 2014.
- SOMMER G, GARTEN A, PETZOLD S, BECK-SICKINGER AG, BLÜHER M, STUMVOLL M, FASSHAUER M: Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. *Clin Sci (Lond)* **115**: 13-23, 2008.
- SONCINI D, CAFFA I, ZOPPOLI G, CEA M, CAGNETTA A, PASSALACQUA M, MASTRACCI L, BOERO S, MONTECUCCO F, SOCIALI G, LASIGLIÈ D, DAMONTE P, GROZIO A, MANNINO E, POGGI A, D'AGOSTINO VG, MONACELLI F, PROVENZANI A, ODETTI P, BALLESTRERO A, BRUZZONE S, NENCIONI A: Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. *J Biol Chem* **289**: 34189-34204, 2014.
- STEPHENS JM, VIDAL-PUIG AJ: An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. *Curr Opin Lipidol* **17**: 128-131, 2006.
- SUN Z, LEI H, ZHANG Z: Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. *Cytokine Growth Factor Rev* **24**: 433-442, 2013.
- TANAKA M, NOZAKI M, FUKUHARA A, SEGAWA K, AOKI N, MATSUDA M, KOMURO R, SHIMOMURA I: Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. *Biochem Biophys Res Commun* **359**: 194-201, 2007.
- WANG S, ZHANG X, TAN L: Serum amyloid a promotes visfatin expression in macrophages. *Biomed Res Int* **2016**: 4819327, 2016.
- ZHAO Y, LIU XZ, TIAN WW, GUAN YF, WANG P, MIAO CY: Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. *CNS Neurosci Ther* **20**: 539-547, 2014.